Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   208 Trials   208 Trials   5617 News 


«12...3738394041424344454647...7172»
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Clinical, Journal:  Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. (Pubmed Central) -  Feb 9, 2021   
    He subsequently derived a clinical benefit with metastatic lung disease regression on trastuzumab emtansine (T-DM1)...The patient's response and disease progression were associated with ongoing decline in the HER2 copy number on the circulating tumor DNA assay, suggesting that the mechanism of resistance was related to the loss of HER2 amplification or the emergence of non-HER2-amplified CRC clones. This represents the first report of clinical benefit with T-DM1 in KRAS-mutated HER2-amplified CRC.
  • ||||||||||  Trial initiation date, Tumor mutational burden:  CRAFT: The NCT-PMO-1602 Phase II Trial (clinicaltrials.gov) -  Feb 9, 2021   
    P2,  N=175, Not yet recruiting, 
    This represents the first report of clinical benefit with T-DM1 in KRAS-mutated HER2-amplified CRC. Initiation date: Nov 2020 --> Apr 2021
  • ||||||||||  Herceptin (trastuzumab) / Roche
    [VIRTUAL] Locally advanced breast cancer () -  Feb 7, 2021 - Abstract #SGBCC2021SG_BCC_54;    
    Coordinated efforts from multidisciplinary teams of oncologists and surgeons can optimize local control of disease and prevent relapses. However, only modest improvements in survival have been achieved between 2000 and 2014 according to SEER data; this observation underscores the remaining unmet need in patients with LABC whose tumor biology is frequently resistant to current treatment regimens and who will benefit from specific research efforts in this disease entity.
  • ||||||||||  paclitaxel / Generic mfg.
    [VIRTUAL] Neoadjuvant and adjuvant treatment of patients with HER2- positive early breast cancer () -  Feb 7, 2021 - Abstract #SGBCC2021SG_BCC_8;    
    Established neoadjuvant regimens in HER2+ EBC are either an anthracycline-taxane sequence plus HP or docetaxel-carboplatin plus dual HER2 blockade (TCbHP)...Newly approved drugs for HER2+ MBC like tucatinib or trastuzumabderuxtecan or even immunotherapy combinations are being evaluated to improve upon efficacy of T-DM1 alone in the non-pCR setting...Further trials looking at therapy individualization according to pCR status after a short de-escalated neoadjuvant regimen of 12 weeks of paclitaxel + HP such as CompassHER2 or ADAPT TP II are still ongoing...While patients with pCR will have a very favorable outcome with adjuvant continuation of trastzumab (± pertuzumab), adjuvant T-DM1 offers an important escalation strategy in case of non-pCR. A multidisciplinary team is essential right from the beginning for optimal locoregional and systemic therapy in such a complex neoadjuvant – adjuvant continuum of care.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date:  HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (clinicaltrials.gov) -  Feb 4, 2021   
    P1,  N=30, Recruiting, 
    PUFFIN adds to the totality of data with pertuzumab in previously untreated HER2-positive locally recurrent or metastatic breast cancer and supports the favorable benefit-risk profile of pertuzumab in Chinese patients TRIAL REGISTRATION: ClinicalTrials.gov, NCT02896855, registered 7 September 2016. Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2021 --> Aug 2021
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  DESTINY-Breast07: A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) -  Feb 3, 2021   
    P1b/2,  N=350, Recruiting, 
    Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2021 --> Aug 2021 Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Apr 2025
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Clinical, Journal:  Neoadjuvant treatment for HER2-positive breast cancer. (Pubmed Central) -  Feb 3, 2021   
    Targeting the HER2 pathway with trastuzumab and pertuzumab can further increase the pCR rate...In the trial, improved invasive disease-free survival (DFS) was observed with the administration of postoperative trastuzumab emtansine in patients with HER2-positive breast cancer who had residual disease after neoadjuvant therapy...Translational studies are promising for further patient selection for HER2-targeted therapy and the development of a novel treatment strategy including PI3K-targeted therapy and immune checkpoint inhibitors. Feasibility studies to evaluate the ability of needle-biopsy to predict pCR after neoadjuvant therapy suggested that standardization and refinements in biopsy procedure (i.e., needle size, number of samples, etc.) are essential for the design of clinical trials of omitted surgery for patients with radiologic complete response.
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Journal:  Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. (Pubmed Central) -  Feb 3, 2021   
    The search included original research articles, abstracts from major conferences, and reviews and was limited to English-language publications. T-DXd is an efficacious and tolerable drug and harbors promise as a key addition to the therapeutic field in HER2-positive breast cancer.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion:  Denosumab as an add-on Neoadjuvant Treatment (GeparX) (clinicaltrials.gov) -  Feb 2, 2021   
    P2,  N=780, Completed, 
    T-DXd is an efficacious and tolerable drug and harbors promise as a key addition to the therapeutic field in HER2-positive breast cancer. Active, not recruiting --> Completed
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Journal:  Pertuzumab for the treatment of breast cancer. (Pubmed Central) -  Jan 29, 2021   
    However, it is imperative to identify patients that will need dual-targeting and mechanisms of resistance. Moreover, the value of pertuzumab beyond progression needs to be evaluated.
  • ||||||||||  Review, Journal:  Systemic therapy for metastatic HER2-positive breast cancer. (Pubmed Central) -  Jan 26, 2021   
    Major treatment challenges remain in the areas of brain metastases and development of drug resistance. This review details an up to date analysis of current and emerging treatments of metastatic HER2-positive breast cancer.
  • ||||||||||  Review, Journal:  Risk-based Approaches for Optimizing Treatment in HER2-Positive Early Stage Breast Cancer. (Pubmed Central) -  Jan 26, 2021   
    Important areas of further research include tailoring the duration and intensity of therapy based on disease risk and response to neoadjuvant therapy. This article will review the evaluation of patients with early stage HER2-positive breast cancer and provide an evidence- and guideline-based summary of risk-based treatment strategies.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal:  Landmark trials in the medical oncology management of early stage breast cancer. (Pubmed Central) -  Jan 26, 2021   
    This progress has led to improvement in survival outcomes and quality of life for our patients. In this review, we discuss landmark clinical trials in medical oncology that have shaped the current standard of care for early stage ER-positive, HER2-positive, and triple negative breast cancer.
  • ||||||||||  Retrospective data, Journal:  HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. (Pubmed Central) -  Jan 26, 2021   
    For HER2 positive unresectable, locally advanced or metastatic patients progressed after trastuzumab therapy pyrotinib plus capecitabine ranked the highest surface under the cumulative ranking area (SUCRA) in PFS, ORR and its SUCRA in OS was higher than Trastuzumab emtansine (T-DM1)...Six of included studies reported any grade ≥3 adverse events, the prevalence of any grade ≥3 adverse events in lapatinib plus capecitabine (353/683), T-DM1 (213/558), trastuzumab plus capecitabine (130/218), pertuzumab plus trastuzumab plus capecitabine (118/228), pyrotinib plus capecitabine (220/384), T-DM1 plus atezolizumab (43/132) and capecitabine (24/94) were 51.7%, 38.2%, 59.6%, 51.8%, 57.3%, 32.6% and 25.5%, respectively...T-DM1 plus atezolizumab, pyrotinib plus capecitabine and pertuzumab plus trastuzumab plus capecitabine have comparable effect on OS improvement and all of them were likely better than T-DM1. The risk of grade ≥3 adverse events for specific treatment regimens were also provided.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Perjeta (pertuzumab) / Roche
    Clinical, Journal:  A Case in Which Re-Administration of Pertuzumab/Trastuzumab with Eribulin Therapy Was Useful for Recurrent HER2 Breast Cancer (Pubmed Central) -  Jan 22, 2021   
    Pertuzumab plus trastuzumab plus docetaxel regimen is the first choice for the initial treatment of HER2-positive recurrent breast cancer...We performed a breast-conserving surgery and sentinel lymph node biopsy, followed by irradiation of the remaining parts of the mammary gland and adjuvant therapy with tamoxifen...The recurrent tumor was HER2-positive, and we administered fluorouracil, epirubicin, cyclophosphamide( FEC)and paclitaxel plus trastuzumab...The liver metastases progressed, and the regimen was changed to pertuzumab plus trastuzumab plus eribulin. Partial response was seen following this regimen for liver metastases without serious adverse events(20 cycles).